Sana Biotechnology (SANA) vs SpyGlass Pharma (SGP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Sana Biotechnology is the larger company by market cap ($835.2 million vs $823.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SANA | SGP |
|---|---|---|
| Share price | $2.79 | $24.62 |
| Market cap | $835.22M | $823.49M |
| 1-day change | +2.57% | +3.01% |
| YTD return | -31.45% | — |
| 1-year return | -38.41% | — |
| 5-year return | -86.58% | — |
| EPS (TTM) | $-0.76 | $-2.51 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.55 | $32.44 |
| 52-week low | $2.61 | $17.06 |
| Distance from 52-week high | -57.40% | -24.11% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +202.15% | +78.72% |
| Average volume | 3.13M | 110.00K |
| Shares outstanding | 299.36M | 33.45M |
| Employees | 142 | 76 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Sana Biotechnology
SANA stock →Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 142 employees
About SpyGlass Pharma
SGP stock →SpyGlass Pharma, Inc. operates as a biopharmaceutical company that provides treatment and drug delivery for patients living with chronic eye conditions.
Health Care · Medical/Dental Instruments · 76 employees
SANA vs SGP FAQ
Which is bigger, Sana Biotechnology or SpyGlass Pharma?
Sana Biotechnology (SANA) is larger, with a market capitalization of $835.22M compared with $823.49M for SpyGlass Pharma (SGP).
Are Sana Biotechnology and SpyGlass Pharma in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Sana Biotechnology and Medical/Dental Instruments for SpyGlass Pharma.